Iovance (IOVA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$325.0M

Revenue (quarter)

$99.3M

Revenue growth (year over year)

+65.65%

Gross profit (trailing twelve months)

$157.3M

Gross margin

48.40%

Net income (trailing twelve months)

−$289.5M

Net income (quarter)

−$47.3M

Net income growth (year over year)

+57.63%

Net margin

−89.09%

Return on equity

−40.36%

EPS (trailing twelve months)

−$0.69

Book value per share

$1.62

P/E (trailing twelve months)

—

Price to book

8.85

Debt to assets

19.60%

Payout ratio

—

Dividend yield

—

Company profile

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

• Is Iovance (IOVA) profitable?

  No. Iovance reported a net loss of $289.5M over the trailing twelve months.

• How much revenue does Iovance (IOVA) make?

  Iovance generated $325.0M in revenue over the trailing twelve months, up 65.65% year over year.

• How do I buy stock in Iovance (IOVA)?

  IOVA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.